Electronic Patient Records to Identify Patients in the United Kingdom with Diabetic Macular Oedema Suitable for ILUVIEN(®) (Fluocinolone Acetonide).

ABSTRACT:

Introduction

We describe a proactive method using electronic patient records (EPR) to identify pseudophakic patients with diabetic macular oedema (DMO) that might benefit from treatment with 0.2 µg/day fluocinolone acetonide (FAc; ILUVIEN(®)) implant.

Methods

Our EPR audit tool (Medisoft(®)) identified diabetic patients (May 2011-December 2014) with National Screening Committee-confirmed grade M1 maculopathy. Searches segmented this DMO patient population into patient groups who: (1) had received ranibizumab therapy, (2) had received ≥2 macular laser treatments, or (3) were unsuitable for macular laser or ranibizumab therapy. Pre-specified criteria identified patients insufficiently responsive to treatment, and their electronic case notes were flagged for clinicians to consi

SUBMITTER: Butt F 

PROVIDER: S-EPMC4909680 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature